These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12418555)

  • 1. Introduction: PROTEKT against respiratory tract infection.
    Stratton CW
    J Chemother; 2002 Jul; 14 Suppl 3():5-8. PubMed ID: 12418555
    [No Abstract]   [Full Text] [Related]  

  • 2. Global surveillance through PROTEKT: the first year.
    Grüneberg RN
    J Chemother; 2002 Jul; 14 Suppl 3():9-16. PubMed ID: 12418556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What can PROTEKT tell us at a local level?
    Inoue M
    J Chemother; 2002 Jul; 14 Suppl 3():17-24. PubMed ID: 12418557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROTEKT years 1-3 (1999-2002): study design and methodology.
    Harding I; Felmingham D
    J Chemother; 2004 Dec; 16 Suppl 6():9-18. PubMed ID: 15690682
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000).
    Felmingham D; Farrell DJ; Reinert RR; Morrissey I
    J Infect; 2004 Jan; 48(1):39-55. PubMed ID: 14667791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rise of fluoroquinolone resistance: fact or fiction.
    Ferraro MJ
    J Chemother; 2002 Jul; 14 Suppl 3():31-41. PubMed ID: 12418559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
    Reinert RR; Rodloff AC; Halle E; Baer W; Beyreiss B; Seifert H; Wichelhaus TA; Maass M; Mehl M
    Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance trends in Streptococcus pyogenes (PROTEKT years 1-3 [1999-2002]).
    Cohen R; Green M
    J Chemother; 2004 Dec; 16 Suppl 6():71-82. PubMed ID: 15690687
    [No Abstract]   [Full Text] [Related]  

  • 10. PROTEKT US: results from the second year of this longitudinal surveillance study of antimicrobial resistance among respiratory tract pathogens isolated from paediatric and adult patients in the USA. Introduction.
    Brown SD
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i5. PubMed ID: 15352301
    [No Abstract]   [Full Text] [Related]  

  • 11. Resistance trends in Haemophilus influenzae (PROTEKT years 1-3 [1999-20021).
    Low DE
    J Chemother; 2004 Dec; 16 Suppl 6():49-61. PubMed ID: 15690685
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV; Brown SD
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction to PROTEkT: years 1-3 (1999-2002).
    Harding I
    J Chemother; 2004 Dec; 16 Suppl 6():5-7. PubMed ID: 15690681
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
    Kohno S; Hoban D;
    J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telithromycin (Ketek) for community-acquired respiratory tract infections.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Sep; 29(9):56-60. PubMed ID: 15359148
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of telithromycin and comparators against isolates of Legionella pneumophila collected from patients with community-acquired respiratory tract infections: PROTEKT Years 1-5.
    Dunbar LM; Farrell DJ
    Clin Microbiol Infect; 2007 Jul; 13(7):743-6. PubMed ID: 17403130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meeting the challenge of antibiotic resistance: The PROTEKT US study.
    Stratton CW
    Postgrad Med; 2002 Sep; 112(3 Suppl):7-11. PubMed ID: 19667589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW; Brown SD
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
    Mendes C; Marin ME; Quiñones F; Sifuentes-Osornio J; Siller CC; Castanheira M; Zoccoli CM; López H; Súcari A; Rossi F; Angulo GB; Segura AJ; Starling C; Mimica I; Felmingham D
    Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.